Updated on March 24, 2021.

In the business world, it’s true that “change is the only constant.”

Think about what Netflix did to Blockbuster video…

As soon as it was possible to deliver several hours of high-quality video content through a standard internet connection, there was no longer a need to drive yourself to a physical Blockbuster location to rent a DVD.

The streaming video technology and business model permanently disrupted the DVD rental business.

There’s nothing new about disruption in the business world.

New technologies have replaced old technologies … and superior business models have supplanted inferior ones … for all of time.

Though, some would argue we’re now on the cusp of a massive tidal wave of new, disruptive technologies and business models that will reshape every industry for decades to come.

And that’s especially true in an industry that’s near and dear to my heart…

Genomics: The Health Care Stocks Disruptor

I was a medical-school dropout before I found my way to the investment world. So I’m still passionate about the broader health care sector.

In October 2019, I presented at an investment conference when I made a pitch for, as I said it, DNA being the future of everything.”

You see, DNA is the foundational “building block” of all living things — humans, cockroaches, even viruses and bacteria.

Thus, the key to understanding all living things is in understanding DNA … and, more poignantly, the specific sequences of DNA that make up the genomes of each living organism.

Once we’re able to read the full sequence of DNA — the “code,” so to speak — we can then understand what that code does in healthy individuals, and in unhealthy ones, who are overtaken by a disease or other ailment.

And that’s why I’m confident the genomic medicine industry will massively disrupt health care stocks — namely the traditional pharmaceutical industry.

Simply put, when you have the ability to fix the root cause of a disease … you no longer need to treat the “downstream” problems it causes in the human body, which is largely what pharmaceuticals do.

We’re already seeing signs of investor interest shifting away from pharma stocks and into genomics stocks.

I like to look at sector exchange-traded funds (ETFs) — which hold a basket of stocks in the same industry — for a broad view of sector performance.

Take a look at the four-year chart of the performance of three ETFs:

  1. A pharmaceuticals ETF (XPH).
  2. A broader health care stocks ETF (XLV).
  3. And the Ark Genomic Revolution ETF (NYSE: ARKG), a genomics ETF I recommended in my investment conference presentation last October:

Past 4 Years: Investors Shift From Pharma to Genomics Stocks

ARKG genomics ETF chart

As you can see, the broader health care sector ETF (in black) is up around 57% over the last four years, while the narrower pharmaceuticals ETF (in red) is up around 23%.

Meanwhile, shares of the Genomic Revolution ETF (ARKG) — in green — have quadrupled over the same time!

COVID-19 Adds Fuel to Genomics ETF (ARKG)

Of course, the COVID-19 pandemic has added fuel to investors’ interest in genomics ETFs and stocks. You can see that clearly in the chart above.

Yet you can also see that genomics stocks were outpacing the pharmaceuticals industry and the broader health care sector for several years before the pandemic hit.

The genomics revolution won’t go away once we’re past the current pandemic. If anything, the pandemic has been both a “test” of this disruptive industry and an accelerator of its importance and acceptance as the future of health care.

Buying shares of the ARK Genomic Revolution ETF (NYSE: ARKG) is a smart way to gain diversified exposure to this cutting-edge disruptive industry.

I’ve also recommended one specific genomic-revolution stock in my premium Green Zone Fortunes service.

This stock’s gains have outpaced ARKG’s nearly 3-to-1 since I recommended it in May 2020, and I think it will continue to be a massive outperformer within the genomic medicine industry for years to come.

Keep your eyes on Money & Markets in the coming week. I’ll share more about why I’m convinced that DNA technology is mankind’s next great leap forward.

You’ll find out more about my conviction that investing in the DNA mega trend now could be like getting into internet stocks in the early 1990s, where rare and exceptional stocks like Intel shot up more than 8,000% in 10 years.

You won’t want to miss it.

To good profits, 

Adam O’Dell 

Chief Investment Strategist